This Core Support Center Grant (P30) application requests continued support for an analytic and synthetic chemistry laboratory and administrative shared core infrastructure. The participating, currently funded, constituent projects continue research programs with human laboratory and treatment clinic studies of the clinical pharmacology of abused drugs, pharmacotherapies and other treatment strategies to treat drug abuse and addictions. Drugs of interest to participating projects and assays available include nicotine and its metabolites, cocaine, methamphetamine and other phenethylamines, alcohol, MDMA, ephedra alkaloids, caffeine, gamma hydroxybutyrate (GHB), salvinorin, adenosine, and neurosteroids, and opiates. Analytical methods have been developed and validated in the core analytic laboratory to support studies with these drugs. Other new assays and labeled (deuterated) compounds will be made available to the associated research projects as needed. Disciplines represented by the participating projects and investigators include psychiatry, clinical psychology, neurology, general internal medicine, cardiology and clinical pharmacology, psychopharmacology, toxicology, genetics, pediatrics, pharmacy, organic, medicinal and analytical chemistry, and statistics.
Our aims are: (1) to provide a state-of-the-art well equipped and staffed, analytical and synthetic chemistry laboratory resource for the participating projects of drug abuse researchers at UCSF and at other institutions. (2) To provide administrative support for manuscript preparation, IRB and related regulatory documents, grants management, and other research administrative services of value participating projects. (3) To provide statistical consulting services regarding study design and data analysis strategies, particularly optimal pharmacokinetic analysis to participating projects. The overall objective is to provide sophisticated analytic laboratory resources with stability of support together with adequate administrative support responsive to the needs of individual funded constituent scientific projects as those projects change and evolve. This facility is a cost-effective shared laboratory resource that enhances and extends research possibilities of investigators currently funded by NIH or other federal or nonfederal sources to further our understanding of human psychoactive drug use, abuse and addiction, its health consequences and its treatment management.

Public Health Relevance

When researching the causes of drug addictions, measuring the health and other consequences of drug use, and searching for effective treatments for addicted people, measures of the amount of drug actually in a person's body are often important. This grant supports a state of the art analytic chemistry laboratory that provides, to a large number of research groups, innovative, sensitive, reliable and cost effective measures of commonly used drugs like nicotine, methamphetamine, opiates and other addicting drugs.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1-EXL-T (06))
Program Officer
Chiang, Nora
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Schools of Medicine
San Francisco
United States
Zip Code
Weinstein, John R; Asteria-Peñaloza, Renée; Diaz-Artiga, Anaité et al. (2017) Exposure to polycyclic aromatic hydrocarbons and volatile organic compounds among recently pregnant rural Guatemalan women cooking and heating with solid fuels. Int J Hyg Environ Health 220:726-735
St Helen, Gideon; Dempsey, Delia A; Havel, Christopher M et al. (2017) Impact of e-liquid flavors on nicotine intake and pharmacology of e-cigarettes. Drug Alcohol Depend 178:391-398
Gubner, Noah R; Guydish, Joseph; Humfleet, Gary L et al. (2017) Nicotine biomarkers and rate of nicotine metabolism among cigarette smokers taking buprenorphine for opioid dependency. Drug Alcohol Depend 178:267-270
Nollen, Nicole L; Mayo, Matthew S; Clark, Lauren et al. (2017) Tobacco toxicant exposure in cigarette smokers who use or do not use other tobacco products. Drug Alcohol Depend 179:330-336
Hang, Bo; Snijders, Antoine M; Huang, Yurong et al. (2017) Early exposure to thirdhand cigarette smoke affects body mass and the development of immunity in mice. Sci Rep 7:41915
Jacob 3rd, Peyton; Benowitz, Neal L; Destaillats, Hugo et al. (2017) Thirdhand Smoke: New Evidence, Challenges, and Future Directions. Chem Res Toxicol 30:270-294
Kassem, Nada O F; Kassem, Noura O; Liles, Sandy et al. (2017) Urinary NNAL in hookah smokers and non-smokers after attending a hookah social event in a hookah lounge or a private home. Regul Toxicol Pharmacol 89:74-82
Taghavi, Taraneh; St Helen, Gideon; Benowitz, Neal L et al. (2017) Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans. Pharmacogenet Genomics 27:143-154
Rait, Michelle A; Prochaska, Judith J; Rubinstein, Mark L (2016) Reporting of cigar use among adolescent tobacco smokers. Addict Behav 53:206-9
Northrup, Thomas F; Jacob 3rd, Peyton; Benowitz, Neal L et al. (2016) Thirdhand Smoke: State of the Science and a Call for Policy Expansion. Public Health Rep 131:233-8

Showing the most recent 10 out of 174 publications